{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:53:47Z","timestamp":1792482827322,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41375-020-0944-4","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T17:26:15Z","timestamp":1593192375000},"page":"2840-2857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Erdheim\u2013Chester disease: a rapidly evolving disease model"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4954-5744","authenticated-orcid":false,"given":"Francesco","family":"Pegoraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Papo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3287-846X","authenticated-orcid":false,"given":"Valerio","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2803-6606","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Charlotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Haroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3814-9172","authenticated-orcid":false,"given":"Augusto","family":"Vaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"944_CR1","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","volume":"127","author":"J-F Emile","year":"2016","unstructured":"Emile J-F, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127:2672\u201381.","journal-title":"Blood"},{"key":"944_CR2","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S1470-2045(17)30031-1","volume":"18","author":"J Haroche","year":"2017","unstructured":"Haroche J, Cohen-Aubart F, Rollins BJ, Donadieu J, Charlotte F, Idbaih A, et al. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol. 2017;18:e113\u201325.","journal-title":"Lancet Oncol"},{"key":"944_CR3","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","volume":"120","author":"J Haroche","year":"2012","unstructured":"Haroche J, Charlotte F, Arnaud L, von Deimling A, H\u00e9lias-Rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim\u2013Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120:2700\u20133.","journal-title":"Blood"},{"key":"944_CR4","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1002\/art.22280","volume":"54","author":"A Stoppacciaro","year":"2006","unstructured":"Stoppacciaro A, Ferrarini M, Salmaggi C, Colarossi C, Praderio L, Tresoldi M, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim\u2013Chester disease: implications for pathogenesis. Arthritis Rheum. 2006;54:4018\u201322.","journal-title":"Arthritis Rheum"},{"key":"944_CR5","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2010-10-313510","volume":"117","author":"L Arnaud","year":"2011","unstructured":"Arnaud L, Gorochov G, Charlotte F, Lvovschi V, Parizot C, Larsen M, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim\u2013Chester disease: a single-center series of 37 patients. Blood. 2011;117:2783\u201390.","journal-title":"Blood"},{"key":"944_CR6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","volume":"33","author":"J Haroche","year":"2015","unstructured":"Haroche J, Cohen-Aubart F, Emile J-F, Maksud P, Drier A, Tol\u00e9dano D, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF V600E-mutated Erdheim\u2013Chester disease. J Clin Oncol. 2015;33:411\u20138.","journal-title":"J Clin Oncol"},{"key":"944_CR7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","volume":"567","author":"EL Diamond","year":"2019","unstructured":"Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567:521\u20134.","journal-title":"Nature"},{"key":"944_CR8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2019003507","volume":"135","author":"G Goyal","year":"2020","unstructured":"Goyal G, Heaney ML, Collin M, Cohen Aubart F, Vaglio A, Durham B, et al. Erdheim\u2013Chester disease: consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era. Blood. 2020;135:1929\u201345.","journal-title":"Blood"},{"key":"944_CR9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood-2013-12-543793","volume":"124","author":"B Hervier","year":"2014","unstructured":"Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, Neel A, et al. Association of both Langerhans cell histiocytosis and Erdheim\u2013Chester disease linked to the BRAFV600E mutation. Blood. 2014;124:1119\u201326.","journal-title":"Blood"},{"key":"944_CR10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/bloodadvances.2016001784","volume":"1","author":"JI Estrada-Veras","year":"2017","unstructured":"Estrada-Veras JI, O\u2019Brien KJ, Boyd LC, Dave RH, Durham BH, Xi L, et al. The clinical spectrum of Erdheim\u2013Chester disease: an observational cohort study. Blood Adv. 2017;1:357\u201366.","journal-title":"Blood Adv"},{"key":"944_CR11","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very G, Vergilio J-A, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919\u201323.","journal-title":"Blood"},{"key":"944_CR12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949\u201354.","journal-title":"Nature"},{"key":"944_CR13","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.3324\/haematol.2018.201194","volume":"104","author":"S Melloul","year":"2019","unstructured":"Melloul S, H\u00e9lias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Fraitag S, Terrones N, et al. Highly sensitive methods are required to detect mutations in histiocytoses. Haematologica. 2019;104:e97\u20139.","journal-title":"Haematologica"},{"key":"944_CR14","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2014-04-570937","volume":"124","author":"J-F Emile","year":"2014","unstructured":"Emile J-F, Diamond EL, H\u00e9lias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, et al. Recurrent RAS and PIK3CA mutations in Erdheim\u2013Chester disease. Blood. 2014;124:3016\u20139.","journal-title":"Blood"},{"key":"944_CR15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","volume":"6","author":"EL Diamond","year":"2016","unstructured":"Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Disco. 2016;6:154\u201365.","journal-title":"Cancer Disco"},{"key":"944_CR16","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood-2015-01-620377","volume":"126","author":"D Gianfreda","year":"2015","unstructured":"Gianfreda D, Nicastro M, Galetti M, Alberici F, Corradi D, Becchi G, et al. Sirolimus plus prednisone for Erdheim\u2013Chester disease: an open-label trial. Blood. 2015;126:1163\u201371.","journal-title":"Blood"},{"key":"944_CR17","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","volume":"25","author":"BH Durham","year":"2019","unstructured":"Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S, et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med. 2019;25:1839\u201342.","journal-title":"Nat Med"},{"key":"944_CR18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood-2016-12-757377","volume":"130","author":"BH Durham","year":"2017","unstructured":"Durham BH, Roos-Weil D, Baillou C, Cohen-Aubart F, Yoshimi A, Miyara M, et al. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem\/progenitor cells. Blood. 2017;130:176\u201380.","journal-title":"Blood"},{"key":"944_CR19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2016-12-757823","volume":"130","author":"P Milne","year":"2017","unstructured":"Milne P, Bigley V, Bacon CM, N\u00e9el A, McGovern N, Bomken S, et al. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim\u2013Chester disease in adults. Blood. 2017;130:167\u201375.","journal-title":"Blood"},{"key":"944_CR20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20130977","volume":"211","author":"ML Berres","year":"2014","unstructured":"Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211:669\u201383.","journal-title":"J Exp Med"},{"key":"944_CR21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature23672","volume":"549","author":"E Mass","year":"2017","unstructured":"Mass E, Jacome-Galarza CE, Blank T, Lazarov T, Durham BH, Ozkaya N, et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature. 2017;549:389\u201393.","journal-title":"Nature"},{"key":"944_CR22","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.lpm.2007.04.032","volume":"36","author":"J Haroche","year":"2007","unstructured":"Haroche J, Amoura Z, Wechsler B, Veyssier-Belot C, Charlotte F, Piette J-C. Maladie d\u2019Erdheim\u2013Chester. La Presse M\u00e9dicale. 2007;36:1663\u20138.","journal-title":"La Presse M\u00e9dicale"},{"key":"944_CR23","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/rheumatology\/kep461","volume":"49","author":"L Dagna","year":"2010","unstructured":"Dagna L, Girlanda S, Langheim S, Rizzo N, Bozzolo EP, Sabbadini MG, et al. Erdheim\u2013Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology. 2010;49:1203\u20136.","journal-title":"Rheumatology"},{"key":"944_CR24","doi-asserted-by":"crossref","first-page":"e1440929","DOI":"10.1080\/2162402X.2018.1440929","volume":"7","author":"G Pacini","year":"2018","unstructured":"Pacini G, Cavalli G, Tomelleri A, De Luca G, Pacini G, Ferrarini M, et al. The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim\u2013Chester disease. Oncoimmunology. 2018;7:e1440929.","journal-title":"Oncoimmunology"},{"key":"944_CR25","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1136\/annrheumdis-2013-204924","volume":"74","author":"MG Cangi","year":"2015","unstructured":"Cangi MG, Biavasco R, Cavalli G, Grassini G, Dal-Cin E, Campochiaro C, et al. BRAF V600E -mutation is invariably present and associated to oncogene-induced senescence in Erdheim\u2013Chester disease. Ann Rheum Dis. 2015;74:1596\u2013602.","journal-title":"Ann Rheum Dis"},{"key":"944_CR26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature03890","volume":"436","author":"C Michaloglou","year":"2005","unstructured":"Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, van der Horst CMAM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720\u20134.","journal-title":"Nature"},{"key":"944_CR27","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/art.22165","volume":"54","author":"J Haroche","year":"2006","unstructured":"Haroche J, Amoura Z, Trad SG, Wechsler B, Cluzel P, Grenier PA, et al. Variability in the efficacy of interferon-\u03b1 in Erdheim\u2013Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum. 2006;54:3330\u20136.","journal-title":"Arthritis Rheum"},{"key":"944_CR28","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.25055","volume":"93","author":"F Cohen-Aubart","year":"2018","unstructured":"Cohen-Aubart F, Emile J-F, Carrat F, Helias-Rodzewicz Z, Taly V, Charlotte F, et al. Phenotypes and survival in Erdheim\u2013Chester disease: results from a 165-patient cohort. Am J Hematol. 2018;93:E114\u20137.","journal-title":"Am J Hematol"},{"key":"944_CR29","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/MPH.0b013e3181b76827","volume":"31","author":"T-A Tran","year":"2009","unstructured":"Tran T-A, Fabre M, Pariente D, Craiu I, Haroche J, Charlotte F, et al. Erdheim\u2013Chester disease in childhood: a challenging diagnosis and treatment. J Pediatr Hematol Oncol. 2009;31:782\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"key":"944_CR30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MPH.0000000000001538","volume":"42","author":"O Tezol","year":"2020","unstructured":"Tezol O, Citak EC, Ayhan YS, Balci Y, Koc ZP, Yuyucu Karabulut Y. Effective high-dose interferon-\u03b1 therapy in a 13-year-old girl with Erdheim\u2013Chester disease. J Pediatr Hematol Oncol. 2020;42:326\u201331.","journal-title":"J Pediatr Hematol Oncol"},{"key":"944_CR31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3171\/2018.6.PEDS17728","volume":"23","author":"X Hao","year":"2019","unstructured":"Hao X, Feng R, Bi Y, Liu Y, Li C, Lu T, et al. Dramatic efficacy of dabrafenib in Erdheim\u2013Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis. J Neurosurg Pediatr. 2019;23:48\u201353.","journal-title":"J Neurosurg Pediatr"},{"key":"944_CR32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s40478-019-0811-6","volume":"7","author":"J Picarsic","year":"2019","unstructured":"Picarsic J, Pysher T, Zhou H, Fluchel M, Pettit T, Whitehead M, et al. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim\u2013Chester disease. Acta Neuropathol Commun. 2019;7:168.","journal-title":"Acta Neuropathol Commun"},{"key":"944_CR33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/annrheumdis-2012-202542","volume":"72","author":"G Cavalli","year":"2013","unstructured":"Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. The multifaceted clinical presentations and manifestations of Erdheim\u2013Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis. 2013;72:1691\u20135.","journal-title":"Ann Rheum Dis"},{"key":"944_CR34","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood-2010-06-294108","volume":"117","author":"L Arnaud","year":"2011","unstructured":"Arnaud L, Hervier B, N\u00e9el A, Hamidou MA, Kahn J-E, Wechsler B, et al. CNS involvement and treatment with interferon-\u03b1 are independent prognostic factors in Erdheim\u2013Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117:2778\u201382.","journal-title":"Blood"},{"key":"944_CR35","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00415-006-0160-9","volume":"253","author":"F Lachenal","year":"2006","unstructured":"Lachenal F, Cotton F, Desmurs-Clavel H, Haroche J, Taillia H, Magy N, et al. Neurological manifestations and neuroradiological presentation of Erdheim\u2013Chester disease: report of 6 cases and systematic review of the literature. J Neurol. 2006;253:1267\u201377.","journal-title":"J Neurol"},{"key":"944_CR36","doi-asserted-by":"publisher","unstructured":"Bhatia A, Hatzoglou V, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, et al. Neurologic and oncologic features of Erdheim\u2013Chester disease: a 30-patient series. Neuro-oncology 2020; https:\/\/doi.org\/10.1093\/neuonc\/noaa008.","DOI":"10.1093\/neuonc\/noaa008"},{"key":"944_CR37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1212\/CPJ.0000000000000422","volume":"8","author":"NE Parks","year":"2018","unstructured":"Parks NE, Goyal G, Go RS, Mandrekar J, Tobin WO. Neuroradiologic manifestations of Erdheim\u2013Chester disease. Neurol Clin Pr. 2018;8:15\u201320.","journal-title":"Neurol Clin Pr"},{"key":"944_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2015.02.004","volume":"95","author":"M Cives","year":"2015","unstructured":"Cives M, Simone V, Rizzo FM, Dicuonzo F, Cristallo Lacalamita M, Ingravallo G, et al. Erdheim\u2013Chester disease: a systematic review. Crit Rev Oncol Hematol. 2015;95:1\u201311.","journal-title":"Crit Rev Oncol Hematol"},{"key":"944_CR39","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1148\/radiol.10090320","volume":"255","author":"A Drier","year":"2010","unstructured":"Drier A, Haroche J, Savatovsky J, Goden\u00e8che G, Dormont D, Chiras J, et al. Cerebral, facial, and orbital involvement in Erdheim\u2013Chester disease: CT and MR imaging findings. Radiology. 2010;255:586\u201394.","journal-title":"Radiology"},{"key":"944_CR40","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-016-0490-3","volume":"11","author":"EL Diamond","year":"2016","unstructured":"Diamond EL, Hatzoglou V, Patel S, Abdel-Wahab O, Rampal R, Hyman DM, et al. Diffuse reduction of cerebral grey matter volumes in Erdheim\u2013Chester disease. Orphanet J Rare Dis. 2016;11:109.","journal-title":"Orphanet J Rare Dis"},{"key":"944_CR41","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/blood.2019002766","volume":"135","author":"J Haroche","year":"2020","unstructured":"Haroche J, Cohen Aubart F, Amoura Z. Erdheim\u2013Chester disease. Blood. 2020;135:1311\u20138.","journal-title":"Blood"},{"key":"944_CR42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/01676830.2016.1176211","volume":"35","author":"H Merritt","year":"2016","unstructured":"Merritt H, Pfeiffer ML, Richani K, Phillips ME. Erdheim\u2013Chester disease with orbital involvement: case report and ophthalmic literature review. Orbit. 2016;35:221\u20136.","journal-title":"Orbit"},{"key":"944_CR43","doi-asserted-by":"crossref","first-page":"E693","DOI":"10.1093\/neuros\/nyz027","volume":"85","author":"JP Marinelli","year":"2019","unstructured":"Marinelli JP, Peters PA, Vaglio A, Van Gompel JJ, Lane JI, Carlson ML. Skull base manifestations of Erdheim\u2013Chester disease: a case series and systematic review. Neurosurgery. 2019;85:E693\u2013701.","journal-title":"Neurosurgery"},{"key":"944_CR44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1210\/jc.2015-3357","volume":"101","author":"C Courtillot","year":"2016","unstructured":"Courtillot C, Laugier Robiolle S, Cohen Aubart F, Leban M, Renard-Penna R, Drier A, et al. Endocrine manifestations in a monocentric cohort of 64 patients with Erdheim\u2013Chester disease. J Clin Endocrinol Metab. 2016;101:305\u201313.","journal-title":"J Clin Endocrinol Metab"},{"key":"944_CR45","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.3174\/ajnr.A2707","volume":"32","author":"P Sedrak","year":"2011","unstructured":"Sedrak P, Ketonen L, Hou P, Guha-Thakurta N, Williams MD, Kurzrock R, et al. Erdheim\u2013Chester disease of the central nervous system: new manifestations of a rare disease. Am J Neuroradiol. 2011;32:2126\u201331.","journal-title":"Am J Neuroradiol"},{"key":"944_CR46","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s12020-018-1737-7","volume":"62","author":"J Herndon","year":"2018","unstructured":"Herndon J, Nadeau AM, Davidge-Pitts CJ, Young WF, Bancos I. Primary adrenal insufficiency due to bilateral infiltrative disease. Endocrine. 2018;62:721\u20138.","journal-title":"Endocrine"},{"key":"944_CR47","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1182\/blood-2016-07-724815","volume":"128","author":"D Gianfreda","year":"2016","unstructured":"Gianfreda D, Palumbo AA, Rossi E, Buttarelli L, Manari G, Martini C, et al. Cardiac involvement in Erdheim\u2013Chester disease: an MRI study. Blood. 2016;128:2468\u201371.","journal-title":"Blood"},{"key":"944_CR48","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1161\/CIRCULATIONAHA.108.767467","volume":"118","author":"A Vaglio","year":"2008","unstructured":"Vaglio A, Corradi D, Maestri R, Callegari S, Buzio C, Salvarani C. Pericarditis heralding Erdheim\u2013Chester disease. Circulation. 2008;118:e511\u20132.","journal-title":"Circulation"},{"key":"944_CR49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00000441-200208000-00008","volume":"324","author":"A Gupta","year":"2002","unstructured":"Gupta A, Kelly B, McGuigan JE. Erdheim\u2013Chester disease with prominent pericardial involvement: clinical, radiologic, and histologic findings. Am J Med Sci. 2002;324:96\u2013100.","journal-title":"Am J Med Sci"},{"key":"944_CR50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","volume":"124","author":"EL Diamond","year":"2014","unstructured":"Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim\u2013Chester disease. Blood. 2014;124:483\u201392.","journal-title":"Blood"},{"key":"944_CR51","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1161\/CIRCULATIONAHA.108.825075","volume":"119","author":"J Haroche","year":"2009","unstructured":"Haroche J, Cluzel P, Toledano D, Montalescot G, Touitou D, Grenier PA, et al. Cardiac involvement in Erdheim\u2013Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation. 2009;119:e597\u20138.","journal-title":"Circulation"},{"key":"944_CR52","first-page":"S-155-63","volume":"33","author":"A Berti","year":"2015","unstructured":"Berti A, Ferrarini M, Ferrero E, Dagna L. Cardiovascular manifestations of Erdheim\u2013Chester disease. Clin Exp Rheumatol. 2015;33:S-155-63.","journal-title":"Clin Exp Rheumatol"},{"key":"944_CR53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/PAT.0b013e32834685d5","volume":"43","author":"P Vaideeswar","year":"2011","unstructured":"Vaideeswar P, Vaz WF. Erdheim\u2013Chester disease with extensive coronary arterial involvement. Pathology. 2011;43:375\u20138.","journal-title":"Pathology"},{"key":"944_CR54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/01.md.0000145368.17934.91","volume":"83","author":"J Haroche","year":"2004","unstructured":"Haroche J, Amoura Z, Dion E, Wechsler B, Costedoat-Chalumeau N, Cacoub P, et al. Cardiovascular Involvement, an overlooked feature of Erdheim\u2013Chester disease: report of 6 new cases and a literature review. Medicine. 2004;83:371\u201392.","journal-title":"Medicine"},{"key":"944_CR55","doi-asserted-by":"crossref","first-page":"e13452","DOI":"10.1097\/MD.0000000000013452","volume":"97","author":"M Villatoro-Villar","year":"2018","unstructured":"Villatoro-Villar M, Bold MS, Warrington KJ, Crowson CS, Goyal G, Shah M, et al. Arterial involvement in Erdheim\u2013Chester disease: a retrospective cohort study. Medicine. 2018;97:e13452.","journal-title":"Medicine"},{"key":"944_CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/BOR.0b013e328341137d","volume":"23","author":"A Vaglio","year":"2011","unstructured":"Vaglio A, Pipitone N, Salvarani C. Chronic periaortitis: a large-vessel vasculitis? Curr Opin Rheumatol. 2011;23:1\u20136.","journal-title":"Curr Opin Rheumatol"},{"key":"944_CR57","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1002\/art.27672","volume":"62","author":"L Arnaud","year":"2010","unstructured":"Arnaud L, Pierre I, Beigelman-Aubry C, Capron F, Brun A-L, Rigolet A, et al. Pulmonary involvement in Erdheim\u2013Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum. 2010;62:3504\u201312.","journal-title":"Arthritis Rheum"},{"key":"944_CR58","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s00330-010-1830-7","volume":"20","author":"A-L Brun","year":"2010","unstructured":"Brun A-L, Touitou-Gottenberg D, Haroche J, Toledano D, Cluzel P, Beigelman-Aubry C, et al. Erdheim\u2013Chester disease: CT findings of thoracic involvement. Eur Radio. 2010;20:2579\u201387.","journal-title":"Eur Radio"},{"key":"944_CR59","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1007\/s00330-018-5421-3","volume":"28","author":"SM Mirmomen","year":"2018","unstructured":"Mirmomen SM, Sirajuddin A, Nikpanah M, Symons R, Paschall AK, Papageorgiou I, et al. Thoracic involvement in Erdheim\u2013Chester disease: computed tomography imaging findings and their association with the BRAFV600E mutation. Eur Radio. 2018;28:4635\u201342.","journal-title":"Eur Radio"},{"key":"944_CR60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/jcm7090243","volume":"7","author":"SG Haroutunian","year":"2018","unstructured":"Haroutunian SG, O\u2019Brien KJ, Estrada-Veras JI, Yao J, Boyd LC, Mathur K, et al. Clinical and histopathologic features of interstitial lung disease in Erdheim\u2013Chester disease. J Clin Med. 2018;7:243.","journal-title":"J Clin Med"},{"key":"944_CR61","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1007\/s00330-018-5326-1","volume":"28","author":"M Nikpanah","year":"2018","unstructured":"Nikpanah M, Kim L, Mirmomen SM, Symons R, Papageorgiou I, Gahl WA, et al. Abdominal involvement in Erdheim\u2013Chester disease (ECD): MRI and CT imaging findings and their association with BRAFV600E mutation. Eur Radio. 2018;28:3751\u20139.","journal-title":"Eur Radio"},{"key":"944_CR62","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2015101110","volume":"27","author":"A Vaglio","year":"2016","unstructured":"Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. JASN. 2016;27:1880\u20139.","journal-title":"JASN"},{"key":"944_CR63","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1148\/rg.2016150213","volume":"36","author":"AS Purysko","year":"2016","unstructured":"Purysko AS, Westphalen AC, Remer EM, Coppa CP, Le\u00e3o Filho HM, Herts BR. Imaging manifestations of hematologic diseases with renal and perinephric involvement. RadioGraphics. 2016;36:1038\u201354.","journal-title":"RadioGraphics"},{"key":"944_CR64","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.urology.2013.10.023","volume":"84","author":"DA Yelfimov","year":"2014","unstructured":"Yelfimov DA, Lightner DJ, Tollefson MK. Urologic manifestations of Erdheim\u2013Chester disease. Urology. 2014;84:218\u201321.","journal-title":"Urology"},{"key":"944_CR65","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1210\/jc.2006-2018","volume":"92","author":"J Haroche","year":"2007","unstructured":"Haroche J, Amoura Z, Touraine P, Seilhean D, Graef C, Birmel\u00e9 B, et al. Bilateral adrenal infiltration in Erdheim\u2013Chester disease. Report of seven cases and literature review. J Clin Endocrinol Metab. 2007;92:2007\u201312.","journal-title":"J Clin Endocrinol Metab"},{"key":"944_CR66","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1148\/radiol.2382041525","volume":"238","author":"E Dion","year":"2006","unstructured":"Dion E, Graef C, Miquel A, Haroche J, Wechsler B, Amoura Z, et al. Bone involvement in Erdheim\u2013Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology. 2006;238:632\u20139.","journal-title":"Radiology"},{"key":"944_CR67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jaad.2015.11.007","volume":"74","author":"F Chasset","year":"2016","unstructured":"Chasset F, Barete S, Charlotte F, Cohen-Aubart F, Arnaud L, Le Pelletier F, et al. Cutaneous manifestations of Erdheim\u2013Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients. J Am Acad Dermatol. 2016;74:513\u201320.","journal-title":"J Am Acad Dermatol"},{"key":"944_CR68","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.3324\/haematol.2019.234187","volume":"105","author":"G Goyal","year":"2020","unstructured":"Goyal G, Ravindran A, Liu Y, He R, Shah MV, Bennani NN, et al. Bone marrow findings in Erdheim\u2013Chester disease: increased prevalence of chronic myeloid neoplasms. Haematologica. 2020;105:e84\u20136.","journal-title":"Haematologica"},{"key":"944_CR69","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood.V124.21.1405.1405","volume":"124","author":"MV Shah","year":"2014","unstructured":"Shah MV, Call TG, Hook CC, Johnston PB, Letendre L, Colgan JP, et al. Clinical presentation, diagnosis, treatment, and outcome of patients with Erdheim\u2013Chester disease: the mayo clinic experience. Blood. 2014;124:1405.","journal-title":"Blood"},{"key":"944_CR70","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1136\/jcp.2004.018481","volume":"57","author":"S-Y Sheu","year":"2004","unstructured":"Sheu S-Y. Erdheim\u2013Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature. J Clin Pathol. 2004;57:1225\u20138.","journal-title":"J Clin Pathol"},{"key":"944_CR71","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s10067-016-3269-y","volume":"35","author":"S Roverano","year":"2016","unstructured":"Roverano S, Gallo J, Ortiz A, Migliore N, Eletti M, Paira S. Erdheim\u2013Chester disease: description of eight cases. Clin Rheumatol. 2016;35:1625\u20139.","journal-title":"Clin Rheumatol"},{"key":"944_CR72","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","volume":"130","author":"F Cohen Aubart","year":"2017","unstructured":"Cohen Aubart F, Emile JF, Carrat F, Charlotte F, Benameur N, Donadieu J, et al. Targeted therapies in 54 patients with Erdheim\u2013Chester disease, including follow-up after interruption (the LOVE study). Blood. 2017;130:1377\u201380.","journal-title":"Blood"},{"key":"944_CR73","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3324\/haematol.2019.216937","volume":"105","author":"J Razanamahery","year":"2020","unstructured":"Razanamahery J, Diamond EL, Cohen-Aubart F, Plate K-H, Lourida G, Charlotte F, et al. Erdheim\u2013Chester disease with concomitant Rosai\u2013Dorfman like lesions: a distinct entity mainly driven by MAP2K1. Haematologica. 2020;105:e5\u20138.","journal-title":"Haematologica"},{"key":"944_CR74","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2017-01-761718","volume":"130","author":"M Papo","year":"2017","unstructured":"Papo M, Diamond EL, Cohen-Aubart F, Emile J-F, Roos-Weil D, Gupta N, et al. High prevalence of myeloid neoplasms in adults with non\u2013Langerhans cell histiocytosis. Blood. 2017;130:1007\u201313.","journal-title":"Blood"},{"key":"944_CR75","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.3324\/haematol.2018.214007","volume":"104","author":"A Roeser","year":"2019","unstructured":"Roeser A, Cohen-Aubart F, Breillat P, Miyara M, Emile J-F, Charlotte F, et al. Autoimmunity associated with Erdheim\u2013Chester disease improves with BRAF\/MEK inhibitors. Haematologica. 2019;104:e502\u20135.","journal-title":"Haematologica"},{"key":"944_CR76","doi-asserted-by":"crossref","first-page":"e3625","DOI":"10.1097\/MD.0000000000003625","volume":"95","author":"D Gianfreda","year":"2016","unstructured":"Gianfreda D, Musetti C, Nicastro M, Maritati F, Cobelli R, Corradi D, et al. Erdheim\u2013Chester disease as a mimic of IgG4-related disease: a case report and a review of a single-center cohort. Medicine. 2016;95:e3625.","journal-title":"Medicine"},{"key":"944_CR77","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.ejrad.2015.04.022","volume":"84","author":"FJ Garc\u00eda-G\u00f3mez","year":"2015","unstructured":"Garc\u00eda-G\u00f3mez FJ, Acevedo-B\u00e1\u00f1ez I, Mart\u00ednez-Castillo R, Tirado-Hospital JL, Cuenca-Cuenca JI, Pach\u00f3n-Garrudo VM, et al. The role of 18FDG, 18FDOPA PET\/CT and 99mTc bone scintigraphy imaging in Erdheim\u2013Chester disease. Eur J Radio. 2015;84:1586\u201392.","journal-title":"Eur J Radio"},{"key":"944_CR78","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/2159-8290.CD-14-0742","volume":"5","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Diamond EL, Vibat CRT, Hassaine L, Poole JC, Patel M, et al. Prospective blinded study of BRAF V600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Disco. 2015;5:64\u201371.","journal-title":"Cancer Disco"},{"key":"944_CR79","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1535-7163.MCT-18-1244","volume":"18","author":"F Janku","year":"2019","unstructured":"Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, et al. Molecular profiling of tumor tissue and plasma cell-free DNA from patients with non-Langerhans cell histiocytosis. Mol Cancer Ther. 2019;18:1149\u201357.","journal-title":"Mol Cancer Ther"},{"key":"944_CR80","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11739-016-1599-z","volume":"12","author":"GM Rossi","year":"2017","unstructured":"Rossi GM, Rocco R, Accorsi Buttini E, Marvisi C, Vaglio A. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. Intern Emerg Med. 2017;12:287\u201399.","journal-title":"Intern Emerg Med"},{"key":"944_CR81","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","volume":"78","author":"ZS Wallace","year":"2019","unstructured":"Wallace ZS, Zhang Y, Perugino CA, Naden R, Choi HK, Stone JH. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis. 2019;78:406\u201312.","journal-title":"Ann Rheum Dis"},{"key":"944_CR82","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.carpath.2015.10.007","volume":"25","author":"D Corradi","year":"2016","unstructured":"Corradi D, Nicastro M, Vaglio A. Immunoglobulin G4-related disease: some missing pieces in a still unsolved complex puzzle. Cardiovasc Pathol. 2016;25:90\u20132.","journal-title":"Cardiovasc Pathol"},{"key":"944_CR83","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0140-6736(08)61077-6","volume":"372","author":"C Salvarani","year":"2008","unstructured":"Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:12.","journal-title":"Lancet"},{"key":"944_CR84","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1111\/jdv.15636","volume":"33","author":"A Amoura","year":"2019","unstructured":"Amoura A, Haroche J, Emile J\u2010F, Barete S, Helias\u2010Rodzewicz Z, Charlotte F, et al. Sarcoidosis occurring during BRAF\/MEK inhibitors is associated with paradoxical ERK activation in Erdheim\u2010Chester patients. J Eur Acad Dermatol Venereol. 2019;33:e348\u201350.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"944_CR85","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00005792-199605000-00005","volume":"75","author":"C Veyssier-Belot","year":"1996","unstructured":"Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, Wechsler J, Brun B, Remy M, et al. Erdheim\u2013Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine. 1996;75:157\u201369.","journal-title":"Medicine"},{"key":"944_CR86","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","volume":"4","author":"EL Diamond","year":"2018","unstructured":"Diamond EL, Subbiah V, Lockhart AC, Blay J-Y, Puzanov I, Chau I, et al. Vemurafenib for BRAF V600\u2013mutant Erdheim\u2013Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4:384\u20138.","journal-title":"JAMA Oncol"},{"key":"944_CR87","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay J-Y, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726\u201336.","journal-title":"N Engl J Med"},{"key":"944_CR88","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.3324\/haematol.2017.185298","volume":"103","author":"A Bhatia","year":"2018","unstructured":"Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, et al. Single-agent dabrafenib for BRAF V600E-mutated histiocytosis. Haematologica. 2018;103:e177\u201380.","journal-title":"Haematologica"},{"key":"944_CR89","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood-2016-09-740217","volume":"129","author":"TM Nordmann","year":"2017","unstructured":"Nordmann TM, Juengling FD, Recher M, Berger CT, Kalbermatten D, Wicki A, et al. Trametinib following disease reactivation under dabrafenib in Erdheim\u2013Chester disease with both BRAF and KRAS mutations. Blood. 2017;129:879\u201382.","journal-title":"Blood"},{"key":"944_CR90","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.mayocpiqo.2018.05.001","volume":"2","author":"A Al Bayati","year":"2018","unstructured":"Al Bayati A, Plate T, Al Bayati M, Yan Y, Lavi ES, Rosenblatt JD. Dabrafenib and trametinib treatment for Erdheim\u2013Chester disease with brain stem involvement. Mayo Clin Proc Innov Qual Outcomes. 2018;2:303\u20138.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"944_CR91","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2011.11.004","volume":"41","author":"B Hervier","year":"2012","unstructured":"Hervier B, Arnaud L, Charlotte F, Wechsler B, Piette JC, Amoura Z, et al. Treatment of Erdheim\u2013Chester disease with long-term high-dose interferon-\u03b1. Semin Arthritis Rheum. 2012;41:907\u201313.","journal-title":"Semin Arthritis Rheum"},{"key":"944_CR92","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.2019004478","volume":"135","author":"F Pegoraro","year":"2020","unstructured":"Pegoraro F, Maniscalco V, Peyronel F, Westenend PJ, Hendriksz TR, Roperto RM, et al. mTOR-inhibition in patients with Erdheim\u2013Chester disease: a long-term follow-up study. Blood. 2020;135:1994\u20137.","journal-title":"Blood"},{"key":"944_CR93","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood-2015-09-672667","volume":"127","author":"F Cohen-Aubart","year":"2016","unstructured":"Cohen-Aubart F, Maksud P, Saadoun D, Drier A, Charlotte F, Cluzel P, et al. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim\u2013Chester disease. Blood. 2016;127:1509\u201312.","journal-title":"Blood"},{"key":"944_CR94","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.14997","volume":"183","author":"G Goyal","year":"2018","unstructured":"Goyal G, Shah MV, Call TG, Litzow MR, Wolanskyj-Spinner AP, Koster MJ, et al. Efficacy of biological agents in the treatment of Erdheim\u2013Chester disease. Br J Haematol. 2018;183:520\u20134.","journal-title":"Br J Haematol"},{"key":"944_CR95","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216610","author":"C Campochiaro","year":"2019","unstructured":"Campochiaro C, Cavalli G, Farina N, Tomelleri A, Luca GD, Dagna L. Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim\u2013Chester disease. Ann Rheum Dis. 2019. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216610.","journal-title":"Ann Rheum Dis"},{"key":"944_CR96","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/annrheumdis-2017-212678","volume":"77","author":"F Cohen-Aubart","year":"2018","unstructured":"Cohen-Aubart F, Maksud P, Emile J-F, Benameur N, Charlotte F, Cluzel P, et al. Efficacy of infliximab in the treatment of Erdheim\u2013Chester disease. Ann Rheum Dis. 2018;77:1387\u201390.","journal-title":"Ann Rheum Dis"},{"key":"944_CR97","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1200\/JCO.2012.41.9911","volume":"30","author":"L Dagna","year":"2012","unstructured":"Dagna L, Corti A, Langheim S, Guglielmi B, De Cobelli F, Doglioni C, et al. Tumor necrosis factor \u03b1 as a master regulator of inflammation in Erdheim\u2013Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol. 2012;30:e286\u201390.","journal-title":"J Clin Oncol"},{"key":"944_CR98","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1093\/rheumatology\/keu344","volume":"53","author":"T-A Tran","year":"2014","unstructured":"Tran T-A, Pariente D, Guitton C, Delwail A, Barat-Houari M, Meinzer U. Treatment of Erdheim\u2013Chester disease with canakinumab. Rheumatol (Oxf). 2014;53:2312\u20134.","journal-title":"Rheumatol (Oxf)"},{"key":"944_CR99","doi-asserted-by":"crossref","first-page":"e1318237","DOI":"10.1080\/2162402X.2017.1318237","volume":"6","author":"A Berti","year":"2017","unstructured":"Berti A, Cavalli G, Guglielmi B, Biavasco R, Campochiaro C, Tomelleri A, et al. Tocilizumab in patients with multisystem Erdheim\u2013Chester disease. OncoImmunology. 2017;6:e1318237.","journal-title":"OncoImmunology"},{"key":"944_CR100","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jamaoncol.2017.0041","volume":"3","author":"G Goyal","year":"2017","unstructured":"Goyal G, Shah MV, Call TG, Litzow MR, Hogan WJ, Go RS. Clinical and radiologic responses to cladribine for the treatment of Erdheim\u2013Chester disease. JAMA Oncol. 2017;3:1253\u20136.","journal-title":"JAMA Oncol"},{"key":"944_CR101","first-page":"647","volume":"7","author":"G Goyal","year":"2017","unstructured":"Goyal G, Shah MV, Call TG, Hook CC, Hogan WJ, Go RS. Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim\u2013Chester disease. Blood. Cancer J. 2017;7:647.","journal-title":"Cancer J"},{"key":"944_CR102","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2017-07-795054","volume":"130","author":"A Vaglio","year":"2017","unstructured":"Vaglio A, Diamond EL. Erdheim\u2013Chester disease: the \u201ctargeted\u201d revolution. Blood. 2017;130:1282\u20134.","journal-title":"Blood"},{"key":"944_CR103","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/bloodadvances.2018030502","volume":"3","author":"EL Diamond","year":"2019","unstructured":"Diamond EL, Reiner AS, Buthorn JJ, Shuk E, Applebaum AJ, Hyman DM, et al. A scale for patient-reported symptom assessment for patients with Erdheim\u2013Chester disease. Blood Adv. 2019;3:934\u20138.","journal-title":"Blood Adv"},{"key":"944_CR104","doi-asserted-by":"crossref","first-page":"e0131635","DOI":"10.1371\/journal.pone.0131635","volume":"10","author":"E Sieni","year":"2015","unstructured":"Sieni E, Barba C, Mortilla M, Savelli S, Grisotto L, Di Giacomo G, et al. Early diagnosis and monitoring of neurodegenerative Langerhans cell histiocytosis. PLoS ONE. 2015;10:e0131635.","journal-title":"PLoS ONE"},{"key":"944_CR105","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s11255-010-9724-9","volume":"42","author":"JE Sanchez","year":"2010","unstructured":"Sanchez JE, Mora C, Macia M, Navarro JF. Erdheim\u2013Chester disease as cause of end-stage renal failure: a case report and review of the literature. Int Urol Nephrol. 2010;42:1107\u201312.","journal-title":"Int Urol Nephrol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0944-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0944-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0944-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:41:26Z","timestamp":1684604486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0944-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":105,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["944"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0944-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}